69
Participants
Start Date
May 3, 2016
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Entrectinib
TRKA/B/C, ROS1, and ALK inhibitor
Memorial Sloan Kettering Cancer Center, New York
Hôpital de la Timone, Oncologie Pédiatrique, Marseille
Children's Hospital of Philadelphia, Philadelphia
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Johns Hopkins University, Baltimore
Hospital Infantil Universitario Nino Jesus, Madrid
Egleston Children's Hospital at Emory University Atlanta, Atlanta
St. Jude Children'S Research Hospital, Memphis
Nationwide Children's Hospital, Columbus
University of Chicago, Chicago
Washington University,St. Louis Children's Hospital, St Louis
Universitaetsklinikum Heidelberg, Heidelberg
Centre Leon Berard, Lyon
Texas Children's Cancer and Hematology Center, Houston
Children's Hospital Colorado, Aurora
Primary Children's Hospital, Salt Lake City
Rady Childrens Hospital, San Diego
UCSF Benioff Children's Hospital, San Francisco
Oregon Health & Science Uni, Portland
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
University of California San Diego, La Jolla
Dana Farber Cancer Institute, Boston
The Hospital for Sick Children, Toronto
Beijing Children's Hospital, Capital Medical University, Beijing
Hong Kong Children's Hospital, Hong Kong
Royal Marsden Hospital (Sutton), London
Royal Victoria Infirmary, Newcastle upon Tyne
Hoffmann-La Roche
INDUSTRY